R Loomba

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Alanine aminotransferase decreases with age: the Rancho Bernardo Study
    Mamie H Dong
    Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 5:e14254. 2010
  2. pmc Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study
    Jeffrey K Lee
    Department of Medicine, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 7:e34218. 2012
  3. ncbi request reprint Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease
    L M Stinton
    Division of Gastroenterology Department of Medicine, University of California San Diego, La Jolla, CA, USA
    Minerva Gastroenterol Dietol 60:5-13. 2014
  4. ncbi request reprint Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma
    Rohit Loomba
    Division of Gastroenterology, University of California at San Diego, La Jolla, California Division of Epidemiology, University of California at San Diego, La Jolla, California Electronic address
    Clin Gastroenterol Hepatol 11:1636-45.e1-3. 2013
  5. pmc Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study
    Rohit Loomba
    Division of Gastroenterology and Division of Epidemiology, University of California at San Diego, 9500 Gilman Drive, MC 0063, La Jolla, CA 92093, USA
    Am J Epidemiol 177:333-42. 2013
  6. pmc Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
    Rohit Loomba
    Division of Gastroenterology, Department of Medicine, and Preventive Medicine, University of California San Diego, La Jolla, CA 92093, USA
    Hepatology 56:943-51. 2012
  7. doi request reprint Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis
    Rohit Loomba
    Division of Gastroenterology, University of California at San Diego, La Jolla, California 92093, USA
    Clin Gastroenterol Hepatol 7:487-93. 2009
  8. pmc Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials
    Rohit Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Gastroenterol Hepatol 6:1243-8. 2008
  9. pmc Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis
    Rohit Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA
    Clin Gastroenterol Hepatol 6:696-700. 2008
  10. ncbi request reprint Treatment of chronic hepatitis B
    Rohit Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MA, USA
    Antivir Ther 12:H33-41. 2007

Collaborators

Detail Information

Publications29

  1. pmc Alanine aminotransferase decreases with age: the Rancho Bernardo Study
    Mamie H Dong
    Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 5:e14254. 2010
    ..This study examines the association between serum ALT and age in a community-dwelling cohort in the United States...
  2. pmc Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study
    Jeffrey K Lee
    Department of Medicine, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 7:e34218. 2012
    ..Interleukin-6 (IL-6) may have a protective role in acute liver disease but a detrimental effect in chronic liver disease. It is unknown whether IL-6 is associated with risk of liver-related mortality in humans...
  3. ncbi request reprint Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease
    L M Stinton
    Division of Gastroenterology Department of Medicine, University of California San Diego, La Jolla, CA, USA
    Minerva Gastroenterol Dietol 60:5-13. 2014
    ....
  4. ncbi request reprint Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma
    Rohit Loomba
    Division of Gastroenterology, University of California at San Diego, La Jolla, California Division of Epidemiology, University of California at San Diego, La Jolla, California Electronic address
    Clin Gastroenterol Hepatol 11:1636-45.e1-3. 2013
    ..We examined how family HCC history and presence or stage of hepatitis B virus (HBV) infection affect risk for HCC...
  5. pmc Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study
    Rohit Loomba
    Division of Gastroenterology and Division of Epidemiology, University of California at San Diego, 9500 Gilman Drive, MC 0063, La Jolla, CA 92093, USA
    Am J Epidemiol 177:333-42. 2013
    ..83, 0.67, and 4.53, respectively, suggesting a multiplicative interaction between alcohol use and obesity. Obesity and alcohol synergistically increase the risk of incident HCC...
  6. pmc Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
    Rohit Loomba
    Division of Gastroenterology, Department of Medicine, and Preventive Medicine, University of California San Diego, La Jolla, CA 92093, USA
    Hepatology 56:943-51. 2012
    ..51 (95% CI: 1.01-2.25; P = 0.04) and 1.49 (95% CI: 1.01-2.20; P = 0.04), respectively...
  7. doi request reprint Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis
    Rohit Loomba
    Division of Gastroenterology, University of California at San Diego, La Jolla, California 92093, USA
    Clin Gastroenterol Hepatol 7:487-93. 2009
    ..Our purpose was to determine the beneficial effect of fluoroquinolones as compared with placebo in primary prophylaxis of SBP in high-risk patients with cirrhosis by using meta-analysis...
  8. pmc Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials
    Rohit Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Gastroenterol Hepatol 6:1243-8. 2008
    ..The aim of our study was to assess the biochemical and histologic changes seen in the placebo arm of the randomized, placebo-controlled trials in adult patients with NASH...
  9. pmc Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis
    Rohit Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA
    Clin Gastroenterol Hepatol 6:696-700. 2008
    ..We aimed to estimate the relative efficacy of combined therapy with hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) versus HBIG monotherapy for preventing HBV-related morbidity and mortality in this setting...
  10. ncbi request reprint Treatment of chronic hepatitis B
    Rohit Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MA, USA
    Antivir Ther 12:H33-41. 2007
    ..In this review, we summarize the current modalities and highlight important issues in the treatment of chronic hepatitis B monoinfection...
  11. pmc Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study
    R Loomba
    Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    Aliment Pharmacol Ther 30:1137-49. 2009
    ..The association between body-mass-index (BMI), alcohol consumption and their joint effect in increasing the risk of elevated serum alanine (ALT) and aspartate (AST) is unclear in older community-dwelling adults...
  12. doi request reprint Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men
    Rohit Loomba
    Division of Gastroenterology, University of California at San Diego, La Jolla, California 92093, USA
    Clin Gastroenterol Hepatol 8:891-8, 898.e1-2. 2010
    ..Body mass index (BMI) and alcohol use are risk factors for hepatocellular carcinoma (HCC). We performed a prospective study to determine if these factors have synergistic effects on HCC risk...
  13. pmc Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
    Rohit Loomba
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U S Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Ann Intern Med 148:519-28. 2008
    ..Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing chemotherapy...
  14. doi request reprint Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease
    N S Patel
    Division of Internal Medicine, Department of Medicine, University of California, San Diego, CA, USA
    Aliment Pharmacol Ther 37:630-9. 2013
    ..Ectopic fat deposition in the pancreas and its association with hepatic steatosis have not previously been examined in patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD)...
  15. pmc Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD
    Z Permutt
    Division of Internal Medicine, Department of Medicine, University of California, San Diego, USA
    Aliment Pharmacol Ther 36:22-9. 2012
    ..Newer MR techniques such as the proton density-fat fraction (PDFF) that correct for these factors have not been specifically compared to liver biopsy in adult patients with non-alcoholic fatty liver disease (NAFLD)...
  16. pmc Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis
    J H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Aliment Pharmacol Ther 38:134-43. 2013
    ..Non-alcoholic steatohepatitis (NASH) is a common cause of serum alanine aminotransferase (ALT) elevations and chronic liver disease, but it is unclear how well ALT elevations reflect the liver injury...
  17. pmc Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
    R Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    Aliment Pharmacol Ther 29:172-82. 2009
    ..Non-alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH...
  18. doi request reprint The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes
    R Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Aliment Pharmacol Ther 33:559-65. 2011
    ..Acute hepatitis C has variable modes of presentation and frequently results in chronic infection. Its optimal management has yet to be defined...
  19. pmc Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
    E Boettcher
    Division of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, CA 92093, USA
    Aliment Pharmacol Ther 35:66-75. 2012
    ..However, the magnitude of treatment response associated with TZDs in improving liver histology in NASH has not been quantified systematically...
  20. ncbi request reprint Novel approaches to new therapies for hepatitis B virus infection
    Rohit Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Antivir Ther 11:1-15. 2006
    ..These advances herald a new era of combination therapy. In this review, we will discuss emerging therapies and potential mechanisms, and highlight the promises and pitfalls of these new treatment strategies...
  21. pmc Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression
    Tara N Palmore
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, MSC 1888, Bethesda, Maryland 20892 1888, USA
    Clin Gastroenterol Hepatol 7:1130-7. 2009
    ..We report 6 patients who experienced loss of serologic markers of hepatitis B immunity and reappearance of HBsAg in the serum as a result of a variety of acquired immune deficiencies...
  22. ncbi request reprint Drug targets in hepatitis B virus infection
    Lance L Stein
    Division of Gastroenterology, Department of Medicine, University of California San Diego, CA, USA
    Infect Disord Drug Targets 9:105-16. 2009
    ..In this review, we will highlight the HBV life cycle and genome, focusing in on current and potential novel antiviral drug targets as well as the benefits and clinical challenges with these therapies...
  23. ncbi request reprint The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
    Glen Lutchman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
    Hepatology 46:424-9. 2007
    ....
  24. pmc Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease
    A Zarrinpar
    Division of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, CA 92093 0063, USA
    Aliment Pharmacol Ther 36:909-21. 2012
    ..Recent research has led to an interest in the role of the gut and liver in type 2 diabetes mellitus (T2DM)...
  25. pmc Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
    Y Rotman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1800, USA
    Aliment Pharmacol Ther 31:1018-27. 2010
    ..Chronic infection with hepatitis C, genotype 2/3, responds better than other genotypes to peginterferon and ribavirin treatment. We hypothesized that a lower dose of peginterferon would be as effective, but less toxic than standard doses...
  26. pmc Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study
    Rohit Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    Gastroenterology 134:953-9. 2008
    ..We sought to examine the relations between parental obesity and the serum ALT and AST levels among offspring in a community-based sample...
  27. pmc Advances in pediatric nonalcoholic fatty liver disease
    Rohit Loomba
    Division of Gastroenterology, Department of Medicine, University of California at San Diego and Rady Children s Hospital, San Diego, CA, USA
    Hepatology 50:1282-93. 2009
    ..Targeted therapies to improve liver histology and metabolic abnormalities associated with fatty liver are needed. Currently, randomized-controlled trials are underway in the pediatric population to define pharmacologic therapy for NAFLD...
  28. pmc Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins
    Rohit Loomba
    Department of Medicine, University of California at San Diego, La Jolla, California, USA
    Gastroenterology 139:836-45, 845.e1. 2010
    ..We estimated the heritability of GGT using a twin-study design and examined the genetic covariance between GGT levels, IR, hypertension, levels of low-density lipoproteins and triglycerides, and ADRB2 variants...